Department of Interventional Radiology, Navy General Hospital , Beijing, China .
Cancer Biother Radiopharm. 2018 Jun;33(5):176-181. doi: 10.1089/cbr.2017.2425.
Pain is a prevalent and serious problem in patients with cancer. This study aimed to investigate the clinical value of the implantation of radioactive particle I in treating cancer and its pain.
From February 2014 to February 2015, 38 patients with malignant tumor received computed tomography (CT)-guided I radioactive particle implantation to treat cancer pain in this hospital. Before surgery, the lesions were calculated by brachytherapy treatment planning system (TPS) to get the local number of particles that are required for implantation. For a period after implantation, TPS was used again to assess the effect of treatment. The 38 patients received 6-month follow-up, and the CT scan was used to evaluate the local tumor. The visual analogue scale (VAS) was used to assess the pain.
The curative effect was evaluated at postoperative 2, 4, and 6 months, and the curative effect was 34.2%, 73.68%, and 89.47%, respectively. The preoperative VAS score of the 38 patients was 5.48 ± 2.50 (13 cases of mild pain, 19 cases of moderate pain, and 6 cases of severe pain), and their pain was improved in different degrees after operation.
CT-guided I radioactive particle implantation is a safe and effective treatment for cancer and its pain.
疼痛是癌症患者中普遍存在且严重的问题。本研究旨在探讨放射性粒子 I 植入治疗癌症及其疼痛的临床价值。
2014 年 2 月至 2015 年 2 月，本院对 38 例恶性肿瘤患者进行 CT 引导下 I 放射性粒子植入治疗癌痛。手术前，采用近距离治疗计划系统（TPS）计算病变部位，得出需要植入的粒子局部数量。植入后一段时间，再次使用 TPS 评估治疗效果。38 例患者接受了 6 个月的随访，通过 CT 扫描评估局部肿瘤。采用视觉模拟评分（VAS）评估疼痛。
术后 2、4、6 个月进行疗效评估，有效率分别为 34.2%、73.68%和 89.47%。38 例患者术前 VAS 评分为 5.48±2.50（轻度疼痛 13 例，中度疼痛 19 例，重度疼痛 6 例），术后疼痛程度均有不同程度的改善。
CT 引导 I 放射性粒子植入术治疗癌症及其疼痛安全有效。
